Skip to main content

News

Arthritis and Suicide Linked with Childhood Adversities

Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.

Dramatic Results for Interferon Blocker in SLE

Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.

Long-Acting Opioids Associated with Higher Mortality Risk

Prescription of long-acting opioids for chronic noncancer pain was associated with an increased risk of all-cause mortality, including deaths from causes other than overdose, compared with anticonvulsants or cyclic antidepressants, according to a study appearing in the June 14 issue of JAMA.

No Increased Risk of Colitis Flares in Secukinumab Trials

No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.

Parathyroidectomy Improves and Bisphosphonates Worsen Fracture Risk in Primary Hyperparathyroidism

A retrospective observational study of over 6000 patients with primary hyperparathyroidism (PHPT), followed in the Kaiser-Permanente system, has shown a greater need for parathyroidectomy than was previously thought.

U-ACT-Early and the Benefits of Tocilizumab

Lancet has published the results of the U-ACT-early study assessing the efficacy of monotherapy versus combination therapy using an interleukin-6 receptor-blocking monoclonal antibody, tocilizumab, in patients with rheumatoid arthritis.

Ixekizumab Success with the UNCOVER Trials in Psoriasis

The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.

Pre-Clinical Use of Rituximab Forestalls Rheumatoid Onset

The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.

Hospitalizations Decline for Rheumatoid Arthritis, But Increase in Gout

JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.

EULAR: Tofacitinib Effective in Ankylosing Spondylitis

Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis. 

GiACTA Study Shows Benefit of Adding Tocilizumab to Steroid Taper in Giant Cell Arteritis

The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA). 

Eight Deaths Linked to Methotrexate in Australia

Methotrexate , a cornerstone drug used to treat rheumatoid arthritis, has led to 90 hospitalizations and 7 deaths according to a recent report from the Medical Journal of Australia. 

Comorbidities Seen with ANCA-Associated Vasculitis

The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.

April-May 2016 Top Social Media News

In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.

RheumNow Week in Review - 3 June 2016

This week's highlights from RheumNow.com include:

×